



**InteliCare Holdings Ltd**  
ABN 84 622 484 397

**ASX Code**  
ICR

#### Corporate Directory

Chief Executive Officer &  
Managing Director  
**Mr Jason Waller**

Non-Exec Chairman  
**Mr Greg Leach**

Non-Executive Director  
**Mr Branden Dekenah**

Non-Executive Director &  
Company Secretary  
**Mr Neil Hackett**

Non-Executive Director  
**Mr Scott Taylor**

**Issued Shares**  
84,169,943

**Unlisted Options**  
20,710,569

#### Company Details

Email  
[investors@intelicare.com.au](mailto:investors@intelicare.com.au)  
Website  
[www.intelicare.com.au](http://www.intelicare.com.au)

#### Registered & Principal Office

Level 1, 299 Vincent St  
Leederville WA 6001

## Entitlement Offer successfully raises \$2.99 million with cornerstone fund

The Board of InteliCare Holding Limited (**Company**) (ASX: ICR) refers to its announcement of 15 November 2021 in relation to the pro-rata non-renounceable entitlement offer to eligible shareholders on the basis of 1 fully paid ordinary share at an issue price of \$0.08 per new share (**New Share**) for every 2.25 Shares held as at 5.00pm (Perth time) on Friday, 19 November 2021 (**Entitlement Offer**).

The Entitlement Offer was strongly supported by eligible shareholders, who applied for 37,408,864 New Shares, raising approximately \$1.3 million (before costs), pursuant to their entitlements. This represents a 44% take up rate of entitlements by eligible shareholders. The Entitlement Offer shortfall was 21,036,101 New Shares which has been allocated by Westar Capital Ltd in accordance with the Underwriting Agreement previously announced on 15 November 2021.

Significantly, the Company is very pleased to welcome a new cornerstone investor, Merchant Biotech Fund, onto the register. Merchant Biotech Fund has a significant record backing early-stage med tech, health tech, biotech and life sciences companies. As a result, Merchant Biotech Fund will hold 6% of the Company's expanded share capital.

Intelicare Chief Executive Officer and Managing Director, Jason Waller, said "We are very happy with the results of this raise and the continuing loyal support of our existing shareholders. Additionally, the quality of our new shareholders is impressive and will greatly assist in shaping our way forward as we continue to build on our record growth."

The New Shares will be issued under the Entitlement Offer on 22 December 2021 and are expected to commence trading on ASX on 23 December 2021. The New Shares to be issued under the Entitlement Offer will rank equally with existing ordinary shares on issue.

*This announcement is approved for release by the Board of InteliCare Holdings Limited.*

**For more information regarding InteliCare, visit [www.intelicare.com.au](http://www.intelicare.com.au).**

#### Contact and Authorised for Release to the ASX

Jason Waller, Chief Executive Officer and Managing Director, InteliCare Holdings Ltd, +61 1300 001 145 , [investors@intelicare.com.au](mailto:investors@intelicare.com.au)

## **About Intelicare Holdings Limited**

*InteliCare is an Australian technology company that has commercialised a predictive analytics hardware and software system for use in the aged care and health industries. InteliCare believes Australians deserve to age with dignity and through its business-to-business (B2B) and business-to-consumer (B2C) solutions built on its proprietary internet of things (IOT) platform utilising smart sensors and artificial intelligence (AI), InteliCare aims to enable people to stay in their own homes for longer while empowering healthcare providers to deliver higher quality, more efficient services.*